4-PrO-DMT

4-PrO-DMT
Clinical data
Other names	4-Propionyloxy-N,N-dimethyltryptamine; 4-Propionyloxy-DMT; 4-Propanoyloxy-DMT; O-Propionylpsilocin
Routes of; administration	Oral
Drug class	Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
	IUPAC name [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate;
CAS Number	1373882-11-1;
PubChem CID	155907598;
ChemSpider	84400449;
UNII	B9BF25HPH4;
CompTox Dashboard (EPA)	DTXSID501336912 ;
Chemical and physical data
Formula	C15H20N2O2
Molar mass	260.337 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)OC1=CC=CC2=C1C(=CN2)CCN(C)C;
	InChI InChI=1S/C15H20N2O2/c1-4-14(18)19-13-7-5-6-12-15(13)11(10-16-12)8-9-17(2)3/h5-7,10,16H,4,8-9H2,1-3H3; Key:KUOGXPDQORRHED-UHFFFAOYSA-N;

4-PrO-DMT, also known as 4-propionyloxy-N,N-dimethyltryptamine or as O-propionylpsilocin, is a synthetic psychedelic drug of the tryptamine family with psychedelic that is believed to act as a prodrug of psilocin (4-HO-DMT). It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019. A number of related derivatives have been synthesized as prodrugs of psilocin for medical applications.